Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beta-Blockers and Cancer: Where Are We?
Rita Peixoto, Maria de Lourdes Pereira, Miguel Oliveira
Pharmaceuticals (2020) Vol. 13, Iss. 6, pp. 105-105
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Breast cancer and neurotransmitters: emerging insights on mechanisms and therapeutic directions
Priya Jayachandran, Francesca Battaglin, Carly Strelez, et al.
Oncogene (2023) Vol. 42, Iss. 9, pp. 627-637
Open Access | Times Cited: 28
Pharmaceutical Contaminants in Wastewater and Receiving Water Bodies of South Africa: A Review of Sources, Pathways, Occurrence, Effects, and Geographical Distribution
Elisa Pandelani Munzhelele, Rabelani Mudzielwana, Wasiu B. Ayinde, et al.
Water (2024) Vol. 16, Iss. 6, pp. 796-796
Open Access | Times Cited: 12
Insights and opportunities at the crossroads of cancer and neuroscience
Chenchen Pan, Frank Winkler
Nature Cell Biology (2022) Vol. 24, Iss. 10, pp. 1454-1460
Closed Access | Times Cited: 37
Repurposing drugs targeting metabolic diseases for cancer therapeutics
Jisha Pillai U, Anindita Ray, Meenu Maan, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 9, pp. 103684-103684
Closed Access | Times Cited: 18
Anticancer effect of propranolol on diethylnitrosamine‐induced hepatocellular carcinoma rat model
Yomna M. Tamim, Ahmed Nagy, Ahmed M. Abdellah, et al.
Fundamental and Clinical Pharmacology (2024) Vol. 38, Iss. 4, pp. 742-757
Closed Access | Times Cited: 7
The Use of Antihypertensive Drugs as Coadjuvant Therapy in Cancer
José Alberto Carlos-Escalante, Marcela de Jesús-Sánchez, Alejandro Rivas-Castro, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 36
The β-Blocker Carvedilol Prevents Benzo(a)pyrene-Induced Lung Toxicity, Inflammation and Carcinogenesis
Ayaz Shahid, Mengbing Chen, Carol Yeh‐Yun Lin, et al.
Cancers (2023) Vol. 15, Iss. 3, pp. 583-583
Open Access | Times Cited: 13
Tumor Neurobiology in the Pathogenesis and Therapy of Head and Neck Cancer
Siyuan Liang, Jochen Heß
Cells (2024) Vol. 13, Iss. 3, pp. 256-256
Open Access | Times Cited: 5
The multifaceted role of beta‐blockers in overcoming cancer progression and drug resistance: Extending beyond cardiovascular disorders
Simona Cavalu, Sameh Saber, Ahmed E. Amer, et al.
The FASEB Journal (2024) Vol. 38, Iss. 13
Open Access | Times Cited: 5
Stress regulatory hormones and cancer: the contribution of epinephrine and cancer therapeutic value of beta blockers
Rajan Kumar Tiwari, Shiv Govind Rawat, Siddharth Rai, et al.
Endocrine (2025)
Closed Access
β-Blockers Influence Oncological Outcomes in Gastric Cancer Patients Treated with Neoadjuvant Chemotherapy Based on the Pathological Subtype: A Retrospective Cohort Study
Nerma Crnovrsanin, Sarah Zumsande, Ingmar F. Rompen, et al.
Annals of Surgical Oncology (2025)
Open Access
The molecular mechanism of chronic stress affecting the occurrence and development of breast cancer and potential drug therapy
Huimin Liu, Le-le Ma, Chunyu Li, et al.
Translational Oncology (2021) Vol. 15, Iss. 1, pp. 101281-101281
Open Access | Times Cited: 25
Cancer catecholamine conundrum
Henning Wackerhage, Jesper Frank Christensen, Matthias Ilmer, et al.
Trends in cancer (2021) Vol. 8, Iss. 2, pp. 110-122
Closed Access | Times Cited: 23
From GWAS to drug screening: repurposing antipsychotics for glioblastoma
Wei-Zhi Lin, Yen‐Chun Liu, Meng-Chang Lee, et al.
Journal of Translational Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 15
The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
Lina S. Farhoumand, Miltiadis Fiorentzis, Miriam M. Kraemer, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3097-3097
Open Access | Times Cited: 14
Gerotherapeutics: Aging Mechanism-based Pharmaceutical and Behavioral Interventions to Reduce Cancer Racial and Ethnic Disparities
Jeanne S. Mandelblatt, Michael H. Antoni, Traci N. Bethea, et al.
JNCI Journal of the National Cancer Institute (2024)
Closed Access | Times Cited: 2
Highlighting the Potential for Chronic Stress to Minimize Therapeutic Responses to Radiotherapy through Increased Immunosuppression and Radiation Resistance
Minhui Chen, Anurag K. Singh, Elizabeth A. Repasky
Cancers (2020) Vol. 12, Iss. 12, pp. 3853-3853
Open Access | Times Cited: 18
Novel evidence for the prognostic impact of β-blockers in solid cancer patients receiving immune checkpoint inhibitors
Xuebing Yan, Peipei Liu, Donglin Li, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109383-109383
Closed Access | Times Cited: 12
Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer
Hannah Y. Chen, Weilu Zhao, Shorook Na’ara, et al.
JCO Precision Oncology (2023), Iss. 7
Open Access | Times Cited: 6
Activation of β2‐adrenergic receptor signals suppresses mesenchymal phenotypes of oral squamous cell carcinoma cells
Shintaro Sakakitani, Katarzyna A. Podyma‐Inoue, Rina Takayama, et al.
Cancer Science (2020) Vol. 112, Iss. 1, pp. 155-167
Open Access | Times Cited: 16
The antagonist of β-adrenergic receptor propranolol inhibits T cell lymphoma growth and enhances antitumor efficacy of cisplatin in vivo: A role of modulated apoptosis, glucose metabolism, pH regulation, and antitumor immune response
Rajan Kumar Tiwari, Shiv Govind Rawat, Ajay Kumar
International Immunopharmacology (2023) Vol. 124, pp. 110825-110825
Closed Access | Times Cited: 5
Subclinical cardiac damage in cancer patients before chemotherapy
Iacopo Fabiani, Giorgia Panichella, Alberto Aimo, et al.
Heart Failure Reviews (2021) Vol. 27, Iss. 4, pp. 1091-1104
Open Access | Times Cited: 12
The OSR9 Regimen: A New Augmentation Strategy for Osteosarcoma Treatment Using Nine Older Drugs from General Medicine to Inhibit Growth Drive
Richard E. Kast
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15474-15474
Open Access | Times Cited: 4
Determinants of Neutral Antagonism and Inverse Agonism in the β2-Adrenergic Receptor
Jacqueline C. Calderón, Passainte Ibrahim, Dorothea Gobbo, et al.
Journal of Chemical Information and Modeling (2024) Vol. 64, Iss. 6, pp. 2045-2057
Closed Access | Times Cited: 1
An In Vitro Investigation of the Antiproliferative and Antimetastatic Effects of Levosimendan: Potential Drug Repurposing for Cervical Cancer
Zsuzsanna Schelz, Hiba F. Muddather, Fatemeh Sheihaki Jaski, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6566-6579
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top